TT-00920 / TransThera Biosci - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Recruiting ➔ Completed | N=30 ➔ 20

Enrollment change • Trial completion

A Phase 1 Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Recruiting ➔ Completed

Trial completion

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Active, not recruiting ➔ Completed | Trial completion date: Nov 2021 ➔ Mar 2022

Trial completion • Trial completion date

A Phase 1 Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: TransThera Sciences (Nanjing), Inc.

New P1 trial

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1; N=42; Active, not recruiting; Sponsor: TransThera Sciences (Nanjing), Inc.; Recruiting ➔ Active, not recruiting; N=72 ➔ 42; Trial completion date: Feb 2021 ➔ Nov 2021; Trial primary completion date: Jan 2021 ➔ Jun 2021

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi Ascending Dose of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: TransThera Sciences (Nanjing), Inc.

Clinical • New P1 trial

[VIRTUAL] TT-00920, a Clinical Stage Novel Phosphodiesterase 9 Inhibitor, Protects Against Heart Failure in a Rat Model of Myocardial Infarction (AHA 2020) - P1 | "After 4-week treatment of vehicle, LCZ696, TT-00920, or TT-00920/Valsartan by oral gavage, efficacy was assessed by echocardiography and cardiac histopathology. TT-00920 reversed LAD-induced left ventricular dysfunction and remodeling, supporting its potential as a novel therapeutic agent for heart failure. The superior efficacy of TT-00920/Valsartan combination suggests that TT-00920 and renin-angiotensin-aldosterone system inhibitors may have additive therapeutic effects in heart failure. TT-00920 is currently being evaluated in Phase 1 clinical study for safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers (NCT04364789)."

Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Myocardial Infarction

Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: TransThera Biosciences Co., Ltd

Clinical • New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure